Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14495-14499

  Gianotti, Robert ^a   Charles, Hearns ^b   Hymes, Kenneth ^b   Chandarana, Hersh ^b   Sigal, Samuel ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastric varices; Janus kinase 2, portal hypertension; Myeloproliferative disorder; Partial splenic embolization; Portal vein thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CEFOTAXIME; CONTRAST MEDIUM; HEMOGLOBIN; HEPARIN; HEPATITIS B SURFACE ANTIGEN; HYDROXYUREA; JANUS KINASE 2; METRONIDAZOLE; MOXIFLOXACIN; NADOLOL; PROTEIN; VIRUS DNA; WARFARIN; JAK2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CASE REPORT; CHOLECYSTECTOMY; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS VARICES; FEMALE; FEVER; FOLLOW UP; GASTROSCOPY; GENE; HEMATEMESIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; JANUS KINASE 2 GENE; LEUKOCYTE COUNT; LIVER HILUS; MICROCATHETER; MYELOPROLIFERATIVE DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACENTESIS; PARTIAL SPLENIC EMBOLIZATION; POINT MUTATION; PORTAL HYPERTENSION; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; SPLEEN INFARCTION; SPLEEN SIZE; SPLENIC VEIN; SPLENIC VEIN OCCLUSION; SPLENOMEGALY; STOMACH VARICES; STOMACH VARICES BLEEDING; THROMBOCYTE COUNT; THROMBOCYTOPHERESIS; VEIN OCCLUSION; COMPLICATION; ENZYMOLOGY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN; PROCEDURES; SPLEEN ARTERY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADULT; EMBOLIZATION, THERAPEUTIC; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; JANUS KINASE 2; MAGNETIC RESONANCE IMAGING; MUTATION; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN; SPLENIC ARTERY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84910131933     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14495     Document Type: Article

References (20)

1. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764 [PMID: 19399912 DOI: 10.1002/hep.22772]
2. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714 [PMID: 17263783 DOI: 10.1111/j.1538-7836.2007.02424.x]
3. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534 [PMID: 17133457 DOI: 10.1002/hep.21435]
4. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120: 4921-4928 [PMID: 23043069 DOI: 10.1182/blood-2011-09-376517]
5. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gäken J, Wendon J, Heaton ND, Mufti GJ. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038 [PMID: 16762626]
6. Qi X, Zhang C, Han G, Zhang W, He C, Yin Z, Liu Z, Bai W, Li R, Bai M, Yang Z, Wu K, Fan D. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study. J Gastroenterol Hepatol 2012; 27: 1036-1043 [PMID: 22142461 DOI: 10.1111/j.1440-1746.2011.07040.x]
7. Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut 2010; 59: 729-735 [PMID: 20551457 DOI: 10.1136/gut.2009.192039]
8. Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, Lin CK, Chan HH, Pan HB. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007; 39: 679-685 [PMID: 17661241 DOI: 10.1055/s-2007-966591]
9. Wils A, van der Linden E, van Hoek B, Pattynama PM. Transjugular intrahepatic portosystemic shunt in patients with chronic portal vein occlusion and cavernous transformation. J Clin Gastroenterol 2009; 43: 982-984 [PMID: 19417681 DOI: 10.1097/MCG.0b013e31819706a4]
10. Jang SY, Kim GH, Park SY, Cho CM, Tak WY, Kim JH, Choe WH, Kwon SY, Lee JM, Kim SG, Kim DY, Kim YS, Lee SO, Min YW, Lee JH, Paik SW, Yoo BC, Lim JW, Kim HJ, Cho YK, Sohn JH, Jeong JY, Lee YH, Kim TY, Kweon YO. Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study. Clin Mol Hepatol 2012; 18: 368-374 [PMID: 23323252 DOI: 10.3350/cmh.2012.18.4.368]
11. Saad WE, Sabri SS. Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Technical Results and Outcomes. Semin Intervent Radiol 2011; 28: 333-338 [PMID: 22942551 DOI: 10.1055/s-0031-1284460]
12. Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 2002; 34: 144-150 [PMID: 11926560 DOI: 10.1016/S1590-8658(02)80246-8]
13. Yin XY, Lu MD, Huang JF, Xie XY, Liang LJ. Color Doppler velocity profile assessment of portal hemodynamics in cirrhotic patients with portal hypertension: correlation with esophageal variceal bleeding. J Clin Ultrasound 2001; 29: 7-13 [PMID: 11180179]
14. Mukaiya M, Hirata K, Yamashiro K, Katsuramaki T, Kimura H, Denno R. Changes in portal hemodynamics and hepatic function after partial splenic embolization (PSE) and percutaneous transhepatic obliteration (PTO). Cancer Chemother Pharmacol 1994; 33 Suppl: S37-S41 [PMID: 8137483 DOI: 10.1007/BF00686666]
15. Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol 2007; 18: 463-481 [PMID: 17446537 DOI: 10.1016/j.jvir.2006.12.734]
16. Spigos DG, Jonasson O, Mozes M, Capek V. Partial splenic embolization in the treatment of hypersplenism. AJR Am J Roentgenol 1979; 132: 777-782 [PMID: 107745 DOI: 10.2214/ajr.132.5.777]
17. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Takesue M, Yoshida K, Kuboki M, Yamamoto S. Improved prognosis of cirrhosis patients with esophageal varices and thrombocytopenia treated by endoscopic variceal ligation plus partial splenic embolization. Dig Dis Sci 2006; 51: 352-358 [PMID: 16534680 DOI: 10.1007/s10620-006-3137-8]
18. Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, Jiang Z, Shan H. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig Liver Dis 2009; 41: 411-416 [PMID: 19070555 DOI: 10.1016/j.dld.2008.10.005]
19. Berk DR, Ahmed A. Portal, splenic, and superior mesenteric vein thrombosis in a patient with latent essential thrombocythemia and hyperhomocysteinemia. J Clin Gastroenterol 2006; 40: 227-228 [PMID: 16633126 DOI: 10.1097/00004836-200603000-00012]
20. Greist A. The role of blood component removal in essential and reactive thrombocytosis. Ther Apher 2002; 6: 36-44 [PMID: 11886575 DOI: 10.1046/j.1526-0968.2002.00394.x]